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Glial tumours are a devastating, poorly understood condition carrying a gloomy prognosis for which clinicians sorely lack reliable
predictive parameters facilitating a sound treatment strategy. Tp73, a p53 family member, expresses two main classes of isoforms –
transactivatory activity (TA)p73 and DTAp73 – exhibiting tumour suppressor gene and oncogene properties, respectively. The
authors examined their expression status in high- and low-grade adult gliomas. Isoform-specific real-time reverse transcription-
polymerase chain reaction was used for the analysis of Tp73 isoform transcript expression in a series of 51 adult patients harbouring
glial tumours, in order to compare tumour grades with each other, and with non-tumoural samples obtained from epileptic patients
as well. Our data demonstrate increase of TAp73 and DTAp73 transcript levels at onset and early stage of the disease. We also show
that DEx2–3 isoform expression in low-grade tumours anticipates clinical and imaging progression to higher grades, and correlates to
the patients’ survival. Expression levels of P1 promoter generated Tp73 isoforms – and particularly DEx2–3 – indeed allow for
prediction of the clinical progression of low-grade gliomas in adults. Our data are the first such molecular biology report regarding
low-grade tumours and as such should be of help for sound decision-making.
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Glioblastomas are divided into primary or de novo, and secondary
tumours originating from low-grade (World Health Organization –
WHO – grade II) progressing to high-grades, that is anaplastic
(WHO grade III) gliomas and eventually to highly malignant
glioblastomas (WHO grade IV). Although our knowledge of the
molecular mechanisms involved in tumorigenesis and progression
has significantly improved over fairly recent years, this has yet to
result in an improved therapeutic strategy. To date, no reliable
parameter has allowed for anticipation of clinical progression from
lower to higher grades. Such criteria would be of paramount
importance in therapeutic management of these patients.
The Tp73 gene, a close relative of the tumour suppressor Tp53
gene, contains two independent promoters P1 and P2 (Melino
et al, 2002). P1 promoter controls the TAp73 transcripts contain-
ing exons 1–3 that encode N-terminal sequences with transacti-
vatory activity (TA), and DEx2, DEx2–3 and DN’ transcripts
collectively designate DTAp73 that lack a fully competent TA
domain (Stiewe et al, 2002a,b). The TAp73 isoform is capable of
inducing cell cycle growth arrest and apoptosis and is also
involved in the response of p53 to death stimuli (Flores et al, 2002).
These features are consistent with a tumour suppressor function.
In contrast, the DTA transcripts do not induce cell growth arrest or
cell death. Significantly, their overexpression in NIH3T3 cells
induces malignant transformation and tumour growth in nude
mice (Stiewe et al, 2002a,b), which is consistent with an oncogene
status. The P2 promoter located downstream of exon 30 controls
DNp73 transcripts lacking the TA domain that likewise exhibit
antiapoptotic activity and are therefore functionally similar to
DTAp73 transcripts (Grob et al, 2001; Nakagawa et al, 2002).
DNp73 has been shown to facilitate the immortalisation of MEFs
and to cooperate with oncogenic Ras in transforming primary
fibroblasts in vitro and in inducing MEF-derived fibrosarcomas in
vivo in nude mice (Petrenko et al, 2003). Because the tetramerisa-
tion domain and the DNA-binding domain of the TAp73 protein
are conserved in DNp73 and DTAp73 isoforms, both have been
shown to exert a dominant-negative activity on TAp73 and p53
through oligomerisation with the two proteins and/or by
competition for p53/TAp73 target genes (Stiewe et al, 2002a,b).
Consistent with these data, upregulation of the DNp73 isoform
has been described in neuroblastomas with poor prognosis and
thereby defines this parameter as a strong and independent
predictor of such poor prognosis (Casciano et al, 2002). Moreover
Bergamaschi et al (2003) and Irwin et al (2003) have shown that
TAp73 is induced by a wide variety of chemotherapeutic agents
and that chemosensitivity is related to TAp73 function.
In view of the potential relevance of Tp73 to tumorigenesis, the
expression status of the gene has been addressed in various
tumour types. Significant results have been achieved only in more
recent works taking into account the recently described DTAp73
transcripts by using appropriate couples of primers, designed to
specifically assess contribution of the DTAp73 isoforms among the
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sdifferent P1-generated transcripts collectively referred to as P1
transcripts (Ng et al, 2000; Cui et al, 2005). The most convincing
evidence to date comes from a work on a series of 100 ovarian
tumours of all the known histological types (Concin et al, 2004).
On the whole, these data point to the activation of the P1 promoter
and the deregulation of P1-controlled DTA p73 isoforms in the
tumorigenic process. Furthermore, because the DN’p73 isoform
is upregulated in ovarian tumours but not in other cancers, the
data argue in favour of a selective deregulation among the P1
transcripts in accordance with types of cancer.
We have undertaken a prospective study in order to determine
the involvement of Tp73 isoforms in gliomagenesis and their
prognostic relevance. In the first part we performed a global
analysis of P1- and P2- generated transcripts on high- and low-
grade gliomas, whereas in the second part we focused on low-grade
gliomas and performed a discriminant analysis of P1- generated
transcripts.
PATIENTS AND METHODS
Patients
Tissues from 51 adult patients harbouring glial tumours were
successively collected during surgery at the Department of
Neurological Surgery, University of Poitiers, France, with signed
informed consent of all patients and the approval of the ethics
committee of the Poitou-Charentes area. These patients were free
from any past medical history, especially with regards to brain
surgery, brain radiation therapy or chemotherapy. Our series also
included three tumour-free patients, operated for refractory
epilepsy, obtained from Neurobiotec
s (Lyon, France) in com-
pliance with the ethics committee. For each patient a sample was
collected at the presumed higher-grade region and named the
‘central’ sample. Whenever deemed reasonable – that is without
significant additional functional risk – a second sample was
harvested in the vicinity of the tumour and called ‘peripheral’.
All patients were treated between January 2002 and May 2003.
Distribution of patients in groups according to the WHO
pathology classification appears in Table 1. Twenty-nine patients
underwent tumour resection, whereas 22 benefited from stereo-
tactic biopsy. The first series, dedicated to Tp73 involvement,
included 28 high-grade and 11 low-grade patients (Table 1A), and
12 were added to this group in a second series focusing on Tp73
isoforms (Table 1B). All low-grade patients had non-enhancing
tumours on MRI imaging, and pathology-proven low-grade
tumours. In all cases progression to a higher grade was
pathology-proven. Tumour diagnosis and grading were established
according to the WHO criteria (Kleihues and Cavenee, 2000) and
were systematically revised by two expert neuropathologists.
Analysis of Tp73 isoform transcripts
Tissue harvesting and preparation Per operative pathology exam
allowed to check glial tumour diagnosis with samples obtained
either from open-sky surgery or stereotactic biopsies. Each tumour
Table 1 (A) Tp73 global analysis aimed to show Tp73 involvement in this first series of patients. (B) Tp73 isoforms discrimination aimed to show specific
isoform involvement on this second series of low-grade tumours patients only. (C) Normalised expression levels of Tp73 isoforms in non-tumoural
(epileptic) and in low- and high-grade gliomas
n Pathology Biopsy-surgery Age
(A) – First series
(Tp73 involvement)
Low grades 11 AII: 6 9–2 43.5 (28–68)
OD II: 5
High grades 28 OD III: 7 6–22 60 (33–79)
GBM: 21
(B) – Second series
(Tp73 isoforms)
Low grades 23 (¼11+12) A II: 8 16–7 42.5 (28–68)
OA II: 6
OD II: 9
(C)
Non tumoural tissue
(normal expression)*
Low-grade gliomas medians (min-max) High-grade gliomas medians
(min-max) n¼28
n¼11 n¼23
P1-p73 ( DCT) 14.81 10.28 (7.33–16.83) 10.28 (4.86–15.72)
P1-p73 2
 DDCt 1 23.05 (0.25–178.12) 23.09 (0.53–986.86)
DNp73 ( DCT) 13.84 14.36 (11.23–17.73) 13.52 (7.91–21.34)
DNp73 2
 DDCt 1 0.69 (0.07–6.08) 1.24 (0.01–60.76)
TAp73 ( DCT) 14.16 8.21 (1.7–16.8) ND
TAp73 2
 DDCt 1 61.82 (0.15–5480.15)
DEx2p73 ( DCT) 13.29 11.24 (5.31–17.14) ND
DEx2p73 2
 DDCt 1 4.14 (0.07 –252.48)
DEx2–3p73 ( DCT) 11.94 7.48 (2.09–15.56) ND
DEx2–3p73 2
 DDCt 1 22.01 (0.08–922.88)
DN’p73 ( DCT) 11.73 11.55 (6.62–16.43) ND
DN’p73 2
 DDCt 1 1.13 (0.04 –34.54)
A¼fibrillary astrocytoma; OA¼oligoastrocytoma; OD¼oligodendroglioma; GBM¼glioblastoma. II, III: tumour grades according to the World Health Organization. Results are
expressed in DCt which is the threshold cycle differences (CtGAPDH-CtGene) and in 2
 DDCt which is the comparative threshold between non-tumoural and tumoural tissue
where DDCt¼DCtTumoural DCtNonTumoural and represents fold change value between tumoural and non-tumoural tissue. P1–p73, TAp73, DEx2p73 and DEx2–3p73 show
significantly increased transcript levels as compared to non-tumoural epileptic tissues (Po10–3, Po10–4, P¼0.01 and P¼0.03, respectively). There is no difference of
expression between low- and high-grade gliomas. (*) Non-tumoural tissue value was based on the analysis of three epileptic patients. The mean of DCt values was considered as
normal expression. (ND: not done).
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ssample was divided into two parts: one was dedicated to smears,
the second was immediately frozen in liquid nitrogen in the
operating room, and stored at –801C until usage.
RNA isolation and complementary DNA preparation Total RNA
was extracted from tumour tissues using the RNAeasy
s Mini Kit
(Qiagen, Courtaboeuf, Paris, France) according to the manufac-
turer’s instructions with minor modifications, for exclusion of
contaminated genomic DNA. The spin-column membranes were
treated with DNase (Qiagen) for 15min at room temperature
before elution. Ten microliters of DNAse-treated total RNA was
transcribed into cDNA using Superscriptt II RnaseH - and
random hexamers (Invitrogene
s, Courtaboeuf, Paris, France).
Real-time reverse transcription-polymerase chain reaction and
relative quantification We assessed levels of Tp73 isoform
mRNA transcripts by real-time quantitative PCR in the ABI
PRISM 7000 sequence detection system (Applera, Courtaboeuf,
Paris, France). Primer sequences are listed in Figure 1. All primers
were queried against the no redundant Human Genome Database.
Probe sequence is 50-CAGTTCAATCTGCTGAGCA-30. All primer
pairs detected a unique specific cDNA. The forward primers for
DEx2p73 as well as for DEx2–3p73 were designed to specifically
recognise on the exon–exon boundaries (exon1/exon3 for
DEx2p73 and exon1/exon4 for DEx2–3p73). Indeed, these primers
could not hybridise on TAp73 transcripts as the selected
boundaries exist only in the variants forms. The forward primer
Sense (5 – 3)   Antisense (5 – 3)
P1–p73  GGAGGGCATGACTACATCTGTCA GCGCGGCTGCTCATCT
∆Np73 GCGCCTACCATGCTGTACGT GCGCGGCTGCTCATCT
TAp73  GCACCACGTTTGAGCACCTC GCAGATTGAACTGGGCCATG
∆Ex2p73 ACGGCTGCAGGGAACCA TGCCCTCCAGGTGGAAGAC
∆Ex2–3p73 TGCAGGCCCAGTTCAATCTG CGGTGTTGGAGGGGATGAC
∆Np73 GGATTCCAGCATGGACGTCTT AGAGGCTCCGCAGCTAGTGA
D
Ex 3 Ex 4 Ex 5 Ex 1 Ex 14 2 Ex
Promoter 1 Promoter 2
∆
∆
∆ TAp73
 Ex 3 Ex 4 Ex 5 Ex 1 Ex 14 2 Ex
∆
∆ ∆Ex2–3p73
∆Np73
Ex 3 Ex 4 Ex 5 Ex 1 Ex 14 2 2 Ex Ex      3
∆Ex2p73
A
Ex4 Ex5 Ex 14 .………… P2 transcript Ex  3’ Ex
Ex 3 Ex 4 2 Ex 5 Ex 1 Ex 14 .………… Ex P1 transcripts P1-p73
Ex4 Ex5 Ex 14 .………… Ex  3’ Ex
Ex 3 Ex 4 2 Ex 5 Ex 1 Ex 14 .………… Ex
Ex4 Ex5 Ex 14 .………… ∆Np73 Ex  3’ Ex
Ex 3 Ex 4 2 Ex 5 Ex 1 Ex 14 .………… Ex
Ex4 Ex5 Ex 14 .………… Ex  3’ Ex Ex  3
Ex 3 Ex 4 2 Ex 5 Ex 1 Ex 14 .………… Ex
B
Ex 3 Ex 4 2 Ex 5
Ex 2 Ex 3 Ex  3’ Ex 4 Ex5 Ex 1
Ex 14 .…………
.………… ∆Ex2–3p73
Ex 1 Ex 14 .…………
Ex 14 .…………
P1 transcripts
Ex
Ex
Ex 4 3 Ex 5 Ex 1 Ex
4 Ex Ex 1 Ex5 Ex 14
Ex 3 Ex 4 2 Ex 5
Ex 2 Ex 3 Ex 4 Ex 5 Ex 1
∆Ex2p73 Ex 14 .…………
.…………
Ex 1 Ex 14 .………… TAp73
Ex 14 .………… ∆Np73
Ex
Ex  3
Ex 4 3 Ex 5 Ex 1 Ex
4 Ex Ex 1 Ex5 Ex 14
C
Figure 1 (A) Genomic organisation of the NH2 terminus of Tp73. Arrows indicate transcriptional start sites. Exons are represented as boxes. The
colours indicate the number of the exons, and white untranslated sequences. Exons 2 and 3 encode for the transactivation domain of the full-length p73
protein. Spliced transcripts regulated by Promoter 1 are labelled TAp3, DEx2p73, DEx2–3p73 and DN’p73. (B) Localisation of the primer pairs (arrows)
and probe (red line) used in the global analysis of promoter 1 encoded transcripts (P1–p73) and promoter 2 encoded transcript (DNp73) by real-time PCR
assays. (C) Localisation of the primer pairs (arrows) used for isoform-specific real-time PCR assays. (D) Sequences of the sense- and antisense-primers used
for the global analysis of promoter 1 generated transcripts (P1–p73) and promoter 2 generated transcript (DNp73) and those of isoform-specific
amplification of individual NH2 terminus Tp73 isoforms. The forward primers for DEx2p73 as well as for DEx2–3p73 were designed on the exon-exon
boundary (exon1/exon3 for DEx2p73 and exon1/exon4 for DEx2–3p73). These primers could not hybridise on TAp73 transcripts as the boundary exists
only in the variants forms. The forward primer used for specific TAp73 amplification is localised in exon 2 and the reverse on the exon3/exon4 boundary and
could only amplifiy TAp73. Specificity for DN’p73 was achieved by the unique combination of the upstream (on exon3) and downstream (on exon 30)
primers.
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sused for specific TAp73 amplification is localised in exon 2 and
the reverse on the exon3/exon4 boundary and could only amplify
TAp73. Specificity for DN’p73 was achieved by the unique
combination of the upstream (on exon3) and downstream (on
exon 30) primers. However, the specific amplification of TAp73,
DEx2p73, DEx2–3p73 and DN’p73 transcripts was checked on gel
and gives as expected a single band of 168, 115, 178 and 90pb. This
specific amplification was confirmed by sequencing the products.
The reactions were carried out first by using the Taqman
s
chemistry for the global screening of P1-generated p73 transcripts
(P1–p73) and P2-generated transcripts (DNp73). We then used
SyberGreen chemistry assessing of discriminant Tp73 isoform
expression. Briefly, the PCR reactions were performed in 25ml
reaction volumes consisting of 1  Taqman Universal PCR
Master-Mix or SyberGreen Universal PCR Master-Mix (Applera),
one out of 20 of the reverse transcription reaction, 300nm of each
primer and 200nm of probe when Taqman chemistry was used.
The samples were submitted to amplification as follows: heating
at 501C for 2min, 951C for 10min followed by 40 cycles at
951C 15s, 601C 1min. Each RNA sample was tested in
duplicate and a negative control was included in every plate. The
computed tomography value was defined as the cycle number (Ct)
at which the fluorescence crossed the threshold. Range of
threshold cycles was Ct: 25–37.6 for P1–TAp73, Ct: 26.9–39.8
for DNp73 Ct: 22.89–39.43 for TAp73, Ct: 26.73–37.33 for
DEx2p73, Ct: 23.24–38.75 for DEx2–3p73 and Ct:30.32–36.36 for
DN’p73. Results were normalised using the endogenous reference
GAPDH. The threshold cycle differences is given in Table 1. The
amplification efficiency of the reference gene was similar to that of
the target genes. We employed the relative quantification method
described in Applied Biosystems User Bulletin No. 2 (Applied
Biosystem User Bulletin, 1997) and by Livak and Schmittgen
(2001), in which the amount of target, normalised to the
endogenous reference GAPDH and relative to the non-tumoural
epileptic tissue, is indicated by the 2
 DDCt formula where
DDCt¼DCtTumoural DCtNonTumoural.
Statistical analysis
The data distribution of expression levels being non-Gaussian,
non-parametric tests were used for data analyses. Increase in
transcript levels of each Tp73 isoform was analysed by signed
tests, whereas differences between tumour tissues were tested by
the Wilcoxon rank sum test. Each isoform was dichotomised
according to its median value. Survival was estimated according to
the Kaplan–Meier method and compared between groups by
means of the log-rank test. For correlations among the various
isoforms and patient age, the threshold cycle differences were used
and the Spearman correlation test was applied. Multivariate
analyses were performed with the Cox proportional hazard model.
Models were fitted for the threshold cycle differences and for the
dichotomised variable. All tests were two-sided and the type I error
was set at 5%. Statistical analyses were performed with use of SAS
Statistical Software (Release 8.02).
RESULTS
Global analysis of P1 – (P1–p73) and P2 – (DNp73) generated
transcript expression levels conducted in 11 patients shows that
P1–p73 transcript levels are increased in low-grade gliomas
(Po10
 3) when compared to epileptic tissue samples taken as
non-tumoural controls (Table 1C). In contrast, tumour samples
displayed no increase of DNp73 transcript levels. The same
observation was carried out in 28 high-grade gliomas (Po10
 3).
Because no significant difference was found in P1–p73 transcript
expression between high- and low-grade tumours, deregulation of
the P1 promoter that generates the TAp73 and DTAp73 isoforms
was likely to occur early in the tumorigenic process. This
upregulation of the P1–p73 transcripts was observed in the centre
of the tumours whatever their grade. In contrast, although the
high-grade tumour periphery still displayed high levels of the
transcript, this expression was significantly (P¼0.031) lower on
the periphery of low-grade tumours (Table 2).
On the whole, these data suggest that low- and high-grade
tumours can be distinguished on the basis of their P1–p73
transcript expression status in their central and peripheral areas.
In addition this selective expression of P1–p73 between these
areas in low-grade tumours argues in favour of an evolving
process.
Analysis of P1-p73 transcripts (TAp73, DEx2p73 and DEx2–
3p73 and DN’p73) shows that TAp73, DEx2p73 and DEx2-3p73
transcripts levels were increased (Po0.05) as compared to the
expression spectrum displayed by non-tumoural, control tissue
(Table 1C and Figure 2). On the contrary, expression of the DN’
isoform in tumour samples did not appear to differ from that of
controls. In addition, expressions of these different isoforms were
correlated to each other as significant associations were observed
between TAp73 and DEx2p73 levels (Po10
 2) and TAp73 and
DEx2–3p73 levels (Po10
 3). These data led to the conclusion that,
with the exception of the DN’ isoform, all P1 transcripts were
upregulated in the tumours. Again, these findings argued in favour
of the early deregulation of the P1 promoter in tumours.
Differences in the expression levels were observed within
tumoural and non-tumoural tissue samples. This observation
was particularly noticeable for TAp73 and DEx2–3p73 transcript
levels with a variation of 430000-fold and 410000-fold within
this groups (lowest versus highest expression). A similar observa-
tion was reported by Concin et al, 2004 concerning ovarian
carcinomas where DEx2–3p73 show in normal tissues a variation
of 47000-fold from the lowest to highest measured. One possible
explanation for this variation range is that this variation may
reflects perceptibly the heterogeneity of the tumours, patient-to-
patient variability or both.
Table 2 Normalised expression levels of P1–p73 and DNp73 on the periphery of the tumour and at the centre of the tumour in low- and high-grade
gliomas
High-grade gliomas median (min-max) Low-grade gliomas median (min-max)
P1–p73 DNp73 P1–p73 DNp73
Periphery of the tumour ( DCT) 9.67 (6.40–15.72) 13.20 (8.50–21.34) 12.16 (8.03–16.83) 14.83 (11.23–17.08)
Fold change between tumoural and non-tumoural tissue 44.92 (0.53–339.37) 1.55 (0.01–40.36) 7.33 (0.24–109.65) 0.69 (0.11 6.08)
Centre of the tumour ( DCT) 10.54 (4.86–15.50) 14.14 (7.91–21.12) 10.23 (7.33 –14.40) 14.36 (12.30–17.73)
Fold change between tumoural and non-tumoural tissue 19.44 (0.62–986.86) 0.81 (0.01–60.76) 23.87 (1.33–178.12) 0.69 (0.07–2.90)
Results are expressed in DCt which is the threshold cycle differences (CtGAPDH-CtGene) and in 2
 DDCt which is the comparative threshold between non-tumoural and
tumoural tissue where DDCt ¼DCtTumoural DCtNonTumoural and represents fold change value between tumoural and non-tumoural tissue. There is a statistically significant
difference for P1–p73 expression between the periphery of the tumour and the centre of the tumour for low-grade gliomas (P¼0.031 in Wilcoxon test).
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sIn order to determine the clinical relevance of these findings
with regards to low-grade glioma outcome, survival analysis was
performed as regards overall survival rates. Taking as references
the median values of mRNA levels of different transcripts – above
and below the 50th percentile of the range of the latter – two
groups were defined. This approach was dictated by the
impossibility of estimating the absolute copy numbers of
transcripts. Group 1 included patients in whom the expression
levels for each transcript species were higher than their respective
median values. Group 2 included patients whose expression levels
were lower or equal to the median values. Among the isoforms,
expression levels of the DEx2–3p73 transcript proved to be a
strong prognostic marker for overall survival in our low-grade
glioma cohort (P¼0.007, Figure 3A). Although 10 out of 12 (83%)
DEx2–3p73 low expressor patients (group 2) were still alive as of
the last follow-up, nine out of eleven (82%) of the high expressor
(group 1) patients were deceased. The median overall survival time
for high expressor patients was 13 months (IC95% 4–20) whereas
median survival time for low expressor patients was not reached.
The high expresssor patients (group 1) had a relative amount of
DEx2-3p73 mRNA 422-fold compared with non-tumoural epi-
leptic tissue whereas patients from group 2 had a relative amount
of DEx2–3p73 mRNA o¼22-fold as compared to non-tumoural
epileptic tissue.
In multivariate analysis including age and DEx2–3p7 expres-
sion, age is a significant prognostic factor (P¼0.017) and a trend
is observed for DEx2–3p73 (P¼0.070). However, when DEx2–3
expression is classified in low and high groups, the only factor that
remains significant, even when age is taken into account, is DEx2–
3p73 (P¼0.025).
A similar observation was also carried out, but to a lesser extent,
for DEx2p73 as high expressor patients had a worse outcome than
did low expressor patients (P¼0.043 and Figure 3B). In contrast,
TAp73 and DN’p73 transcripts did not appear to be involved as the
survival rates in the two groups were similar (P¼0.144 and
P¼0.906, respectively Figure 3C and D).
As we know that the neutralising role of these transdominant
forms take place through oligomerisation with TAp73 and p53
proteins it is crucial to confirm that RNA overexpression of the
pronostic splice variants as far as proteins are concerned.
Unfortunately no specific antibodies for any of the DTAp73 forms
currently exist. We cannot therefore propose the existence of a
dominant negative mechanism with DEx2–3p73 and DEx2p73
variants in low-grade gliomas. However, as mRNA expression
of DEx2–3p73 and to a lesser extent DEx2p73 appeared to be
correlated to low-grade gliomas patients survival and to be a
strong prognostic marker in these tumours, our data, although
suggestive on the nefastious role of these transcripts, do not allow
to definitely conclude on this point.
DISCUSSION
Tp73 involvement in glial tumorigenesis
The role of the Tp73 gene in oncogenic process has been
underlined by several reports dealing with different tumour types.
Results including ours have clearly shown that the expression
of the gene rises frequently in a number of tumours although
considerable variations in the levels of transcripts from patient to
patient can be noted (Concin et al, 2004). A previous work dealing
with gliomas and using a semiquantitative RT-PCR assay has
shown that a similar situation also exists in this type of tumour as
overexpression of TAp73 mRNA occurred in high-grade gliomas
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Figure 2 Box plot diagrams showing the normalised expression levels DCt (CtGAPDH-gene) of promoter 1- generated Tp73 isoforms (TAp73,
DEx2p73, DEx2–3p73 and DN’p73) in 23 low-grade gliomas tumours and three non-tumoural tissues. The line within the boxes indicates the median
expression level. The top edge of the boxes represent the 75th percentile, the bottom edge, the 25th percentile. The range is shown as a vertical edge.
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swhereas only a few tumours displayed DNp73 expression (Ugur
et al, 2004). The present study confirms these data and extends
them by reporting increase in transcript levels of the P1-generated
Tp73 transcripts, namely TAp73, DEx2p73 and DEx2-3p73, (but
not DN’p73) in a cohort of low-grade adult gliomas. Interestingly
DNp73 transcript does not appear to differ from that of control
samples. Thus, deregulation of the P1 promoter and emergence of
particular RNA populations are likely to be an early event as this
deregulation is likewise observed in high-grade gliomas and could
possibly influence cell evolution toward malignancy.
The abundance of Tp73 mRNA isoforms in specific cell type is
complex and is likely to result from differential expression, RNA
stability and splicing. In our study, increase in transcript levels of
P1-generated isoforms could be explained by coupled mechanisms:
activation of the P1 promoter itself and selective splicing process
leading to an increase of certain mRNA species (TAp73, DEx2p73
and DEx2–3p73 but not DN’p73). The expression of some
transcripts could be restricted to particular areas of the tumour
suggesting differential splicing in this area. Addressing this
question would require to perform RNA status analysis of at the
individual tumour cells level.
The selective patterns of expression of the transdominantTp73
gene isoforms observed in a variety of tumours (Ng et al, 2000; Cui
et al, 2005), should reflect a particular distribution of the factors
that contribute to splicing such as HnRNP proteins. Incidentally,
several reports have shown the existence of particular populations
of HnRNP proteins in a variety of tumours suggesting that their
expression is implicated in selective activation of gene isoforms
expression (Carpenter et al, 2006).
Tumour-specific variants have been reported to affect transcript
stability and thus, accumulation of the variant transcripts could
result from an increased stability. Regarding this point, impaired
mRNA turnover and stability are shown to play a critical role in
the activation of specific genes during the cellular response to
mitogens, immunological triggers stressful stimuli and differentia-
tion agents (Bashirullah et al, 2001; Fan et al, 2002). Several
parameters control the mRNA turnover: RNA-binding proteins
(RBPs) that bind to specific RNA sequences and either increase or
decrease the transcript half-life (Brennan and Steitz, 2001;
Gorospe, 2003;); regions located in the 30-untranslated regions
(30-UTRs) of mRNA. In the latter, differences in 30-UTRs of splice
variants could be recognised by proteins expressed specifically in
some normal tissues or tumoural tissues or in a particular areas of
the tumour (Jensen and Whitehead, 2004). Finally, the RBP HuR,
upon binding to RNA HuR, has been shown to stabilise it and
alter its translation (Brennan and Steitz, 2001; Gorospe, 2003;
Mazan-Mamczarz et al, 2003).
Another aspect is the differential expression of Tp73 transcripts
in the peripheral and central areas of low-grade tumours as
compared to high-grade gliomas that overexpress the gene in both
areas. Beside the possibility of discriminating between high- and
low-grade tumours, this result suggests that malignant cells from
the periphery of low-grade gliomas differ from those located in the
tumour centre. By using the two dimensional profiling strategy
Li et al (2006) found a large number of genes that showed
coordinated changes in transcript abundance and splicing,
indicating that many distinct steps in gene expression from
transcription, stability control and splicing may be coupled in
different cell types (Li et al, 2006). In view of this observation it is
tempting to speculate that the peripheral cells in low-grade
tumours that differ from their central area congeners may
evolve toward a more malignant stage or disappear to be replaced
by tumour cells coming from the centre. We are considering
the possibility of addressing these hypothesis by carrying
out transcriptome analysis of tumour areas isolated by micro-
dissection.
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Figure 3 Kaplan–Meier survival curves in 23 low-grade gliomas. Two groups were defined taking as reference the median values of the mRNA levels of
different transcripts (above and below the 50th percentile of the range of the different transcripts). (A) DEx 2–3p73, (B) DEx2p73, (C) TAp3 and (D)
DN’p73.
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A survival analysis aimed at determining the clinical relevance of
the increase in DTAp73 isoform transcript levels in low-grade
adult gliomas showed that patients with higher DEx2–3p73
contents in their tumours presented shorter survival than those
with lower amounts of this transcript. Strikingly, increase in the
TAp73 isoform transcript levels was also found in all patients,
thereby arguing in favour of a dominant negative role for the
DEx2–3p73 isoform in survival. This situation mimics that of
ovarian tumours where a better overall survival was noted for
patients exhibiting low expression of the DN’p73 isoform than
for those with high expression, whatever the levels of TAp73
in the tumours (Concin et al, 2004). Moreover, DEx2–3p73 is a
prognostic factor in low-grade gliomas even when age is considered.
Up until now, the status of the Tp73 gene involving its various
isoforms has been examined in ovarian tumours, hepatocarcino-
mas, vulval cancers, oesophagus and gliomas (this report) (Ng
et al, 2000; Cui et al, 2005). Although these studies point to
increase in transcript levels of transdominant DTAp73 isoforms, it
may be noted that, depending on the tumour pathology, a selective
expression of one of the transdominant isoforms appears to be
detected in certain tumour types, supporting the notion that
among the various P1-generated isoforms, differential regulation
exists. Given the necessarily limited number of patients included in
this study, our data strongly suggest that the DEx2–3p73 isoform
is selectively expressed in gliomas. It will be of interest to extend
these observations to other tumour types in order to determine
whether a more specific expression spectrum exists. Obviously,
such selective patterns should reflect an abnormal distribution in
tumour cells of the factors that contribute to splicing. In any case,
whatever the identity of the expressed transdominant DTAp73
isoform, the biological significance directly relies on the neutrali-
sing role of this transdominant form to TAp73 and/or p53.
Although the gross natural history of adult low-grade glioma is
known, a given individual outcome remains unpredictable. This
lack of individual predictive factors results in daunting difficulties
once therapeutic decisions are involved. When a low-grade glioma
is newly diagnosed, clinicians have to decide when to proceed to
treatment: not too early because therapeutic means – extensive
surgical removal, radiation therapy, chemotherapy – are contest-
able as pertains to a benign tumour, but not too late either, that is
before progression to higher grades of these infiltrating tumours.
Up until now the indicators of such a change are clinical symptoms
and imaging changes (e.g. contrast enhancement) but they only
accompany, and fail to anticipate clinical tumour progression. New
criteria allowing for earlier detection of tumour grade progression
and correspondingly more expeditious therapeutic adaptation
would be of heightened value as regards optimal treatment of these
patients. Nevertheless, the use of DEx2–3p73 as such an indicator
has one limitation, which is inherent to our methodology: as there
exists no absolute quantification of this increase in transcript
levels, it has got to be compared with a non-tumoural control
group.
In conclusion, to the best of our knowledge this is the first
report of a single molecular prognostic marker criterion for low-
grade glioma survival in adults. This could lead to early
treatment of the newly diagnosed adult patients harbouring low-
grade gliomas and exhibiting increase in transcript levels of DEx
2–3p73.
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